MELA takes the guesswork out of diagnosing skin cancer
Created when NASDAQ:MELA was $4.01 | Edit | History
All Dermatologists are not equally talented. This instrument can back up their diagnosis and give them an extra test they can perform to avoid malpractice suits etc. It's also non-invasive. What Dermatologist wouldn't want that?